Skip navigation
Browser upgrade notice
  • Paul Fortin: Selected Publications

    • Hudson M, Bernatsky S, Taillefer S, Fortin PR, Wither J, Baron M; Canadian Scleroderma Research Group (CSRG); Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. J Clin Epidemiol. 2008 Jul;61(7):654-62. [Pub Med ID 18342489]
    • Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcón GS, Merrill JT, Clarke A, Bernatsky S, Dooley MA, Fortin PR, Gladman D, Steinsson K, Petri M, Bruce IN, Manzi S, Khamashta M, Zoma A, Font J, Van Vollenhoven R, Aranow C, Ginzler E, Nived O, Sturfelt G, Ramsey-Goldman R, Kalunian K, Douglas J, Qiufen Qi K, Thompson K, Farewell V; Systemic Lupus International Collaborating Clinics. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008 May 15;59(5):721-9. [Pub Med ID 18438902]
    • Graham DS, Vyse TJ, Fortin PR, Montpetit A, Cai YC, Lim S, McKenzie T, Farwell L, Rhodes B, Chad L, Hudson TJ, Sharpe A, Terhorst C, Greenwood CM, Wither J, Rioux JD; CaNIOS GenES Investigators. Association of LY9 in UK and Canadian SLE families. Genes Immun. 2008 Mar;9(2):93-102. [Pub Med ID 18216865]
    • Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcón GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT; Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study. Arthritis Rheum. 2008 Feb 29;58(3):843-853. [Pub Med ID 18311802]
    • Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum. 2008 Feb 15;59(2):169-75. [Pub Med ID 18240259]
    • Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman D, Urowitz M, Wither JE. Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J Immunol. 2008 Jan 15;180(2):1276-84. [Pub Med ID 18178868]
    • Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1) :74-9. [Pub Med ID 17545189]
    • Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making. 2007 Mar-Apr;27(2):138-50. [Pub Med ID 17409364]
    • Bin J, Bernatsky S, Gordon C, Boivin JF, Ginzler E, Gladman D, Fortin PR, Urowitz M, Manzi S, Isenberg D, Rahman A, Petri M, Nived O, Sturfeldt G, Ramsey-Goldman R, Clarke AE. Lung cancer in systemic lupus erythematosus. Lung Cancer. 2007 Jun;56(3):303-6. [Pub Med ID 17291624]
    • Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senécal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE; the Tri-Nation Study Group. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum. 2007 Feb 15;57(1):64-70. [Pub Med ID 17266095]
    • Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcón GS, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007 Jan;56(1):265-73. [Pub Med ID 17195230]
    • Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, Senécal JL, Zummer M, Edworthy S, Sibley J, Pope J, Ensworth S, Ramsey-Goldman R, Hanly JG. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835-9. [Pub Med ID 17211987]
    • Gignac MA, Davis AM, Hawker G, Wright JG, Mahomed N, Fortin PR, Badley EM. “What do you expect? You’re just getting older”: A comparison of perceived osteoarthritis-related and aging-related health experiences in middle- and older-age adults. Arthritis Rheum. 2006 Nov 30;55(6):905-912. [Pub Med ID 17139636] Abstract & Supplementary Information
    • Bernatsky S, Clarke A, Pope J, Hanly JG, Smith CD, Peschken C, Rich E, Boire G, Fortin PR. Malignancy prevalence in the first-degree relatives of persons with systemic lupus erythematous: a pilot study. Lupus. 2006;15(10):695-6. [Pub Med ID 17120599]
    • Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. [Pub Med ID 16868977]
    • Chang ER, Pineau CA, Bernatsky S, Neville C, Clarke AE, Fortin PR. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol. 2006 Sep;33(9):1780-4. [Pub Med ID 16832849]
    • Tisseverasinghe A, Lim S, Greenwood C, Urowitz M, Gladman D, Fortin PR. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum. 2006 Jul;54(7):2211-9. [Pub Med ID 16802357]
    • Chagnon P, Schneider R, Hebert J, Fortin PR, Provost S, Belisle C, Gingras M, Bolduc V, Perreault C, Silverman E, Busque L. Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis Rheum. 2006 Apr;54(4):1270-8. [Pub Med ID 16575839]
    • Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Subang R, Chang ER, Fortin PR. The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies. Rheumatology (Oxford). 2006 Sep;45(9):1116-20. [Pub Med ID 16510527]
    • Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Steinsson K, Nived O, Sturfelt G, St Pierre Y, Clarke A. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005 Oct;64(10):1507-9. [Pub Med ID 16162903]
    • Sarabi ZS, Chang E, Bobba R, Ibanez D, Gladman D, Urowitz M, Fortin PR. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2005 Aug 15;53(4):609-12. [Pub Med ID 16082635]
    • Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res. 2005 Jun;14(5):1333-44. [Pub Med ID 16047508]
    • Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005 May;52(5):1481-90. [Pub Med ID 15880596]
    • Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology (Oxford). 2005 Jun;44(6):751-5. [Pub Med ID 15757968]
    • Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective. J Rheumatol. 2005 Mar;32(3):443-53. [Pub Med ID 15742435]
    • Bobba R, Landolt-Marticorena C, Fortin PR. Thrombosis and inflammation: a question in need of an answer. J Rheumatol. 2005 Mar;32(3):397-9. [Pub Med ID 15742423]
    • Benk V, Al-Herz A, Gladman D, Urowitz M, Fortin PR. Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. Arthritis Rheum. 2005 Feb 15;53(1):67-72. [Pub Med ID 15696566]
    • Kassis J, Neville C, Rauch J, Busque L, Chang ER, Joseph L, Le Comte M, Subang R, Fortin PR. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost. 2004 Dec;92(6):1312-9. [Pub Med ID 15583739]
    • Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod J, Joseph L, St Pierre Y, Fortin PR, Sutcliffe N, Richard Goulet J, Choquette D, Grodzicky T, Esdaile JM; Tri-Nation Study Group. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford). 2004 Aug;43(8):1016-24. [Pub Med ID 15173602]
    • Hudson M, Herr AL, Rauch J, Neville C, Chang E, Ibrahim R, Seguin C, Kassis J, Busque L, Fortin PR. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003 Nov;30(11):2385-91. [Pub Med ID 14677182]
    • Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol. 2003 Oct;30(10):2112-22. [Pub Med ID 14528503]
    • Yen JC, Abrahamowicz M, Dobkin PL, Clarke AE, Battista RN, Fortin PR. Determinants of discordance between patients and physicians in their assessment of lupus disease activity. J Rheumatol. 2003 Sep;30(9):1967-76. [Pub Med ID 12966600]
    • Leung FK, Fortin PR. Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol. 2003 Aug;30(8):1871-3. [Pub Med ID 12913950]
    • Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, Fortin PR. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost. 2003 Jul;90(1):108-15. [Pub Med ID 12876633]
    • Edworthy SM, Dobkin PL, Clarke AE, Da Costa D, Dritsa M, Fortin PR, Barr S, Ensworth S, Esdaile JM, Beaulieu A, Zummer M, Senecal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino A, Gladman D, Devins GM. Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol. 2003 May;30(5):1011-6. [Pub Med ID 12734897]
    • Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, Liang MH, Fortin PR. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus. 2003;12(4):280-6. [Pub Med ID 12729051]
    • Ligier S, Pham CD, Watters AK, Kassis J, Fortin PR. Purpura fulminans and anticardiolipin antibodies in a patient with Grave’s disease. Scand J Rheumatol. 2002;31(6):371-3. [Pub Med ID 12492254]
    • Fortin PR, Penrod JR, Clarke AE, St-Pierre Y, Joseph L, Belisle P, Liang MH, Ferland D, Phillips CB, Mahomed N, Tanzer M, Sledge C, Fossel AH, Katz JN. Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2002 Dec;46(12):3327-30. [Pub Med ID 12483739]
    • Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients’ or physicians’ evaluations of recent lupus activity. J Rheumatol. 2002 Nov;29(11):2350-8. [Pub Med ID 12415591]
    • Chopra N, Koren S, Greer WL, Fortin PR, Rauch J, Fortin I, Senecal JL, Docherty P, Hanly JG. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol. 2002 Aug;29(8):1683-8. [Pub Med ID 12180730]
    • Mahomed NN, Liang MH, Cook EF, Daltroy LH, Fortin PR, Fossel AH, Katz JN. The importance of patient expectations in predicting functional outcomes after total joint arthroplasty. J Rheumatol. 2002 Jun;29(6):1273-9. [Pub Med ID 12064846]
    • Liang MH, Lew RA, Stucki G, Fortin PR, Daltroy L. Measuring clinically important changes with patient-oriented questionnaires. Med Care. 2002 Apr;40(4 Suppl):II45-51. [Pub Med ID 12064581]
    • Dobkin PL, Da Costa D, Joseph L, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile JM, Beaulieu A, Zummer M, Senecal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino A, Gladman D, St-Pierre Y, Clarke AE. Counterbalancing patient demands with evidence: results from a pan-Canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002 Spring;24(2):88-99. [Pub Med ID 12054324]
    • Chang E, Abrahamowicz M, Ferland D, Fortin PR; CaNIOS Investigators. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol. 2002 May;55(5):488-97. [Pub Med ID 12007552]
    • Dobkin PL, Da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile JM, Senecal JL, Goulet JR, Choquette D, Rich E, Beaulieu A, Cividino A, Ensworth S, Smith D, Zummer M, Gladman D, Clarke AE. Living with lupus: a prospective pan-Canadian study. J Rheumatol. 2001 Nov;28(11):2442-8. [Pub Med ID 11708416]
    • Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331-7. [Pub Med ID 11665973]
    • Neville C, Whalley D, McKenna S, Le Comte M, Fortin PR. Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada. J Rheumatol. 2001 Jul;28(7):1505-10. [Pub Med ID 11469454]
    • Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001 Mar;28(3):525-32. [Pub Med ID 11296953]
    • Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 2000 Nov;27(11):2597-604. [Pub Med ID 11093439]
    • Dobkin PL, Da Costa D, Dritsa M, Fortin PR, Senecal JL, Goulet JR, Choquette D, Rich E, Beaulieu A, Cividino A, Edworthy S, Barr S, Ensworth S, Esdaile JM, Gladman D, Smith D, Zummer M, Clarke AE. Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 1999 Dec;12(6):401-10. [Pub Med ID 11081011]
    • Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, St Pierre Y, Joseph L, Penrod J, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE. The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum. 2000 Jun;43(6):1410-8. [Pub Med ID 10857802]
    • Fortin PR, Abrahamowicz M, Clarke AE, Neville C, Du Berger R, Fraenkel L, Liang MH. Do lupus disease activity measures detect clinically important change? J Rheumatol. 2000 Jun;27(6):1421-8. [Pub Med ID 10852264]
    • Galperin I, Fortin PR, Subang R, Newkirk MM, Rauch J. A subset of rheumatoid factors crossreacts with cardiolipin in patients positive for IgM rheumatoid factor and anticardiolipin antibodies. J Rheumatol. 2000 Mar;27(3):820-1. [Pub Med ID 10743835]
    • Neville C, Clarke AE, Joseph L, Belisle P, Ferland D, Fortin PR. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol. 2000 Mar;27(3):675-9. [Pub Med ID 10743807]
    • Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, Senecal JL, Goulet JR, Rich E, Choquette D, Clarke AE. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol. 2000 Feb;27(2):365-72. [Pub Med ID 10685798]
    • Lucey MD, Newkirk MM, Neville C, Lepage K, Fortin PR. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol. 2000 Feb;27(2):319-23. [Pub Med ID 10685791]
    • Yen JC, Neville C, Fortin PR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus. 1999;8(8):660-70. [Pub Med ID 10568904]
    • Ferland D, Fortin PR. Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). Lupus. 1999;8(8):606-11. [Pub Med ID 10568896]
    • Da Costa D, Dobkin PL, Pinard L, Fortin PR, Danoff DS, Esdaile JM, Clarke AE. The role of stress in functional disability among women with systemic lupus erythematosus: a prospective study. Arthritis Care Res. 1999 Apr;12(2):112-9. [Pub Med ID 10513499]
    • Neville C, Fortin PR, Fitzcharles MA, Baron M, Abrahamowitz M, Du Berger R, Esdaile JM. The needs of patients with arthritis: the patient’s perspective. Arthritis Care Res. 1999 Apr;12(2):85-95. [Pub Med ID 10513496]
    • Fortin PR, Clarke AE, Joseph L, Liang MH, Tanzer M, Ferland D, Phillips C, Partridge AJ, Belisle P, Fossel AH, Mahomed N, Sledge CB, Katz JN. Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery. Arthritis Rheum. 1999 Aug;42(8):1722-8. [Pub Med ID 10446873]
    • Da Costa D, Clarke AE, Dobkin PL, Senecal JL, Fortin PR, Danoff DS, Esdaile JM. The relationship between health status, social support and satisfaction with medical care among patients with systemic lupus erythematosus. Int J Qual Health Care. 1999 Jun;11(3):201-7. [Pub Med ID 10435840]
    • Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, St Pierre Y, Joseph L, Penrod J, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Danoff DS, Ho V, Esdaile JM. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 1999 Jul;26(7):1500-11. [Pub Med ID 10405937]
    • Moore AD, Clarke AE, Danoff DS, Joseph L, Belisle P, Neville C, Fortin PR. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices. J Rheumatol. 1999 Jun;26(6):1285-90. [Pub Med ID 10381044]
    • Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol. 1999 Apr;26(4):808-15. [Pub Med ID 10229401]
    • Newkirk MM, Apostolakos P, Neville C, Fortin PR. Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J Rheumatol. 1999 Mar;26(3):597-603. [Pub Med ID 10090169]
    • Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol. 1998 Dec;37(12):1307-14. [Pub Med ID 9973155]
    • Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost. 1998 Dec;80(6):936-41. [Pub Med ID 9869164]
    • Mata S, Chhem RK, Fortin PR, Joseph L, Esdaile JM. Comprehensive radiographic evaluation of diffuse idiopathic skeletal hyperostosis: development and interrater reliability of a scoring system. Semin Arthritis Rheum. 1998 Oct;28(2):88-96. [Pub Med ID 9806369]
    • Benk V, Ho V, Fortin PR, Zhang G, Levinton C, Freeman CR. Predictors of delay in starting radiation treatment for patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):109-15. [Pub Med ID 9588924]
    • Fortin PR, Abrahamowicz M, Neville C, du Berger R, Fraenkel L, Clarke AE, Danoff D. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus. 1998;7(2):101-7. [Pub Med ID 9541094]
    • Dobkin PL, Fortin PR, Joseph L, Esdaile JM, Danoff DS, Clarke AE. Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. Arthritis Care Res. 1998 Feb;11(1):23-31. [Pub Med ID 9534490]
    • Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol. 1998 Feb;25(2):277-84. [Pub Med ID 9489819]
    • Hudson N, Busque L, Rauch J, Kassis J, Fortin PR. Familial antiphospholipid syndrome and HLA-DRB gene associations. Arthritis Rheum. 1997 Oct;40(10):1907-8. [Pub Med ID 9336432]
    • Mata S, Fortin PR, Fitzcharles MA, Starr MR, Joseph L, Watts CS, Gore B, Rosenberg E, Chhem RK, Esdaile JM. A controlled study of diffuse idiopathic skeletal hyperostosis. Clinical features and functional status. Medicine (Baltimore). 1997 Mar;76(2):104-17. [Pub Med ID 9100738]
    • Fortin PR. Vasculitides associated with malignancy. Curr Opin Rheumatol. 1996 Jan;8(1):30-3. [Pub Med ID 8867536]
    • Fortin PR, Abrahamowicz M, Danoff D. Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests. J Rheumatol. 1995 Nov;22(11):2078-83. [Pub Med ID 8596148]
    • Fortin PR, Lew RA, Liang MH, Wright EA, Beckett LA, Chalmers TC, Sperling RI. Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. J Clin Epidemiol. 1995 Nov;48(11):1379-90. [Pub Med ID 7490601]
    • Liang MH, Fortin PR. Response criteria for clinical trials in systemic lupus erythematosus. Lupus. 1995 Oct;4(5):336-8. Erratum in: Lupus 1997;6(7):619. [Pub Med ID 8563726]
    • Fortin PR, Stucki G, Katz JN. Measuring relevant change: an emerging challenge in rheumatologic clinical trials. Arthritis Rheum. 1995 Aug;38(8):1027-30. [Pub Med ID 7639797]
    • Fortin PR, Larson MG, Watters AK, Yeadon CA, Choquette D, Esdaile JM. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group--a review of 45 cases. J Rheumatol. 1995 Jan;22(1):78-84. [Pub Med ID 7699687]
    • Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994 Jan 24;154(2):157-63. [Pub Med ID 8285810]
    • Mata S, Hill RO, Joseph L, Kaplan P, Dussault R, Watts CS, Fitzcharles MA, Shiroky JB, Fortin PR, Esdaile JM. Chest radiographs as a screening test for diffuse idiopathic skeletal hyperostosis. J Rheumatol. 1993 Nov;20(11):1905-10. [Pub Med ID 8308777]
    • Rochon PA, Fortin PR, Dear KB, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med. 1993 Jan 25;153(2):243-8. [Pub Med ID 8422212]
    • Heath CW Jr, Fortin PR. Epidemiologic studies of rheumatoid arthritis: future directions. J Rheumatol Suppl. 1992 Jan;32:74-7. [Pub Med ID 1613736]
    • Fortin PR. Quality assurance in Canada: does insurance affect assurance? J Rheumatol. 1992 Jan;19(1):11-3. [Pub Med ID 1556670]
    • Fortin PR, Fraser RS, Watts CS, Esdaile JM. Alpha-1 antitrypsin deficiency and systemic necrotizing vasculitis. J Rheumatol. 1991 Oct;18(10):1613-6. [Pub Med ID 1684994]
    • Liang MH, Stern S, Fortin PR, Louie DC, Marsh JD, Mudge GH Jr, Murphy G. Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: a new syndrome presenting with facial swelling and pericardial tamponade. Arthritis Rheum. 1991 Feb;34(2):228-33. [Pub Med ID 1994922]
    • Liang MH, Fortin PR, Isenberg DA, Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int. 1991;11(3):133-6. [Pub Med ID 1754816]
    • Miller MA, Lebel F, Fortin PR. Tuberculosis of the skull. AJR Am J Roentgenol. 1990 Nov;155(5):1141. [Pub Med ID 2120959]